CYTOSORBENTS CORP (CTSO) Stock Price, Forecast & Analysis
USA - NASDAQ:CTSO - US23283X2062 - Common Stock
CTSO Key Statistics, Chart & Performance
The current stock price of CTSO is 0.6655 USD. In the past month the price decreased by -26.5%. In the past year, price decreased by -25.64%.
CTSO Latest News, Press Relases and Analysis
CTSO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.9 | 224.97B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.68 | 202.72B | ||
| BSX | BOSTON SCIENTIFIC CORP | 35.59 | 155.55B | ||
| SYK | STRYKER CORP | 28.35 | 142.76B | ||
| IDXX | IDEXX LABORATORIES INC | 55.63 | 56.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.51 | 50.56B | ||
| RMD | RESMED INC | 25.47 | 36.79B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.12 | 33.77B | ||
| DXCM | DEXCOM INC | 32.11 | 23.42B | ||
| PODD | INSULET CORP | 72.79 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.2 | 17.94B |
Related stock screener links
About CTSO
Company Profile
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 149 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Company Info
CYTOSORBENTS CORP
305 College Road East
Princeton NEW JERSEY 08852 US
CEO: Phillip P. Chan
Employees: 149
Phone: 19733298885
CYTOSORBENTS CORP / CTSO FAQ
What does CTSO do?
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 149 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
What is the current price of CTSO stock?
The current stock price of CTSO is 0.6655 USD. The price increased by 4.16% in the last trading session.
Does CYTOSORBENTS CORP pay dividends?
CTSO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTSO stock?
CTSO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for CTSO stock?
8 analysts have analysed CTSO and the average price target is 5.1 USD. This implies a price increase of 666.34% is expected in the next year compared to the current price of 0.6655.
What is the Price/Earnings (PE) ratio of CYTOSORBENTS CORP (CTSO)?
CYTOSORBENTS CORP (CTSO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is the next earnings date for CTSO stock?
CYTOSORBENTS CORP (CTSO) will report earnings on 2026-03-01, after the market close.
CTSO Technical Analysis
CTSO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTSO. CTSO has a bad profitability rating. Also its financial health evaluation is rather negative.
CTSO Financial Highlights
Over the last trailing twelve months CTSO reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 54.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.29% | ||
| ROE | -81.17% | ||
| Debt/Equity | 1.17 |
CTSO Forecast & Estimates
8 analysts have analysed CTSO and the average price target is 5.1 USD. This implies a price increase of 666.34% is expected in the next year compared to the current price of 0.6655.
For the next year, analysts expect an EPS growth of 58.39% and a revenue growth 0.37% for CTSO